vs
Side-by-side financial comparison of Ingevity Corp (NGVT) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $185.4M, roughly 1.6× Ingevity Corp). Bio-Techne runs the higher net margin — 12.8% vs -45.6%, a 58.5% gap on every dollar of revenue. On growth, Ingevity Corp posted the faster year-over-year revenue change (36.7% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs -26.2%).
Ingevity Corp is a global specialty chemicals and advanced materials manufacturer. It produces high-performance carbon materials, pavement preservation solutions, and specialty chemicals, serving automotive emissions control, industrial purification, road infrastructure, and agricultural input markets across North America, Europe, and Asia Pacific.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
NGVT vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $185.4M | $295.9M |
| Net Profit | $-84.6M | $38.0M |
| Gross Margin | 41.2% | 64.6% |
| Operating Margin | -47.7% | 18.4% |
| Net Margin | -45.6% | 12.8% |
| Revenue YoY | 36.7% | -6.4% |
| Net Profit YoY | -609.6% | 68.3% |
| EPS (diluted) | $-2.33 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.4M | $295.9M | ||
| Q3 25 | $333.1M | — | ||
| Q2 25 | $365.1M | $317.0M | ||
| Q1 25 | $284.0M | $316.2M | ||
| Q4 24 | $135.6M | $297.0M | ||
| Q3 24 | $333.8M | $289.5M | ||
| Q2 24 | $390.6M | $306.1M | ||
| Q1 24 | $340.1M | $303.4M |
| Q4 25 | $-84.6M | $38.0M | ||
| Q3 25 | $43.5M | — | ||
| Q2 25 | $-146.5M | $-17.7M | ||
| Q1 25 | $20.5M | $22.6M | ||
| Q4 24 | $16.6M | $34.9M | ||
| Q3 24 | $-107.2M | $33.6M | ||
| Q2 24 | $-283.7M | $40.6M | ||
| Q1 24 | $-56.0M | $49.1M |
| Q4 25 | 41.2% | 64.6% | ||
| Q3 25 | 40.2% | — | ||
| Q2 25 | 37.8% | 62.7% | ||
| Q1 25 | 39.9% | 67.9% | ||
| Q4 24 | 81.3% | 65.3% | ||
| Q3 24 | 39.4% | 63.2% | ||
| Q2 24 | 31.5% | 66.4% | ||
| Q1 24 | 29.3% | 67.4% |
| Q4 25 | -47.7% | 18.4% | ||
| Q3 25 | 18.7% | — | ||
| Q2 25 | -39.1% | -7.5% | ||
| Q1 25 | 9.4% | 12.2% | ||
| Q4 24 | — | 16.0% | ||
| Q3 24 | 33.0% | 13.8% | ||
| Q2 24 | 25.9% | 15.0% | ||
| Q1 24 | 22.6% | 22.1% |
| Q4 25 | -45.6% | 12.8% | ||
| Q3 25 | 13.1% | — | ||
| Q2 25 | -40.1% | -5.6% | ||
| Q1 25 | 7.2% | 7.1% | ||
| Q4 24 | 12.2% | 11.7% | ||
| Q3 24 | -32.1% | 11.6% | ||
| Q2 24 | -72.6% | 13.3% | ||
| Q1 24 | -16.5% | 16.2% |
| Q4 25 | $-2.33 | $0.24 | ||
| Q3 25 | $1.18 | — | ||
| Q2 25 | $-4.02 | $-0.11 | ||
| Q1 25 | $0.56 | $0.14 | ||
| Q4 24 | $0.44 | $0.22 | ||
| Q3 24 | $-2.94 | $0.21 | ||
| Q2 24 | $-7.81 | $0.26 | ||
| Q1 24 | $-1.54 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $78.1M | $172.9M |
| Total DebtLower is stronger | $1.2B | $260.0M |
| Stockholders' EquityBook value | $29.7M | $2.0B |
| Total Assets | $1.7B | $2.5B |
| Debt / EquityLower = less leverage | 39.10× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $78.1M | $172.9M | ||
| Q3 25 | $83.4M | — | ||
| Q2 25 | $76.9M | $162.2M | ||
| Q1 25 | $71.5M | $140.7M | ||
| Q4 24 | $68.0M | $177.5M | ||
| Q3 24 | $135.5M | $187.5M | ||
| Q2 24 | $107.4M | $152.9M | ||
| Q1 24 | $88.5M | $145.3M |
| Q4 25 | $1.2B | $260.0M | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | $346.0M | ||
| Q1 25 | $1.3B | $330.0M | ||
| Q4 24 | $1.3B | $300.0M | ||
| Q3 24 | $1.4B | $300.0M | ||
| Q2 24 | $1.4B | $319.0M | ||
| Q1 24 | $1.4B | $389.0M |
| Q4 25 | $29.7M | $2.0B | ||
| Q3 25 | $138.1M | — | ||
| Q2 25 | $120.7M | $1.9B | ||
| Q1 25 | $234.6M | $2.0B | ||
| Q4 24 | $195.2M | $2.1B | ||
| Q3 24 | $214.5M | $2.1B | ||
| Q2 24 | $284.8M | $2.1B | ||
| Q1 24 | $568.2M | $2.0B |
| Q4 25 | $1.7B | $2.5B | ||
| Q3 25 | $1.8B | — | ||
| Q2 25 | $1.9B | $2.6B | ||
| Q1 25 | $2.1B | $2.6B | ||
| Q4 24 | $2.0B | $2.7B | ||
| Q3 24 | $2.2B | $2.7B | ||
| Q2 24 | $2.3B | $2.7B | ||
| Q1 24 | $2.6B | $2.7B |
| Q4 25 | 39.10× | 0.13× | ||
| Q3 25 | 8.39× | — | ||
| Q2 25 | 10.24× | 0.18× | ||
| Q1 25 | 5.68× | 0.16× | ||
| Q4 24 | 6.86× | 0.14× | ||
| Q3 24 | 6.52× | 0.14× | ||
| Q2 24 | 4.92× | 0.15× | ||
| Q1 24 | 2.48× | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $97.1M | — |
| Free Cash FlowOCF − Capex | $73.5M | — |
| FCF MarginFCF / Revenue | 39.6% | — |
| Capex IntensityCapex / Revenue | 12.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $273.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $97.1M | — | ||
| Q3 25 | $129.7M | — | ||
| Q2 25 | $79.0M | $98.2M | ||
| Q1 25 | $25.4M | $41.1M | ||
| Q4 24 | $64.5M | $84.3M | ||
| Q3 24 | $46.5M | $63.9M | ||
| Q2 24 | $29.7M | $75.5M | ||
| Q1 24 | $-12.1M | $81.0M |
| Q4 25 | $73.5M | — | ||
| Q3 25 | $117.8M | — | ||
| Q2 25 | $66.8M | $93.3M | ||
| Q1 25 | $15.4M | $31.0M | ||
| Q4 24 | $39.6M | $77.5M | ||
| Q3 24 | $28.5M | $54.7M | ||
| Q2 24 | $11.6M | $57.5M | ||
| Q1 24 | $-28.7M | $64.5M |
| Q4 25 | 39.6% | — | ||
| Q3 25 | 35.4% | — | ||
| Q2 25 | 18.3% | 29.4% | ||
| Q1 25 | 5.4% | 9.8% | ||
| Q4 24 | 29.2% | 26.1% | ||
| Q3 24 | 8.5% | 18.9% | ||
| Q2 24 | 3.0% | 18.8% | ||
| Q1 24 | -8.4% | 21.3% |
| Q4 25 | 12.7% | — | ||
| Q3 25 | 3.6% | — | ||
| Q2 25 | 3.3% | 1.5% | ||
| Q1 25 | 3.5% | 3.2% | ||
| Q4 24 | 18.4% | 2.3% | ||
| Q3 24 | 5.4% | 3.2% | ||
| Q2 24 | 4.6% | 5.9% | ||
| Q1 24 | 4.9% | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | 2.98× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.24× | 1.82× | ||
| Q4 24 | 3.89× | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NGVT
| Performance Materials | $151.2M | 82% |
| Advanced Polymer Technologies Segment | $36.5M | 20% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
